MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acs.jmedchem.6c02080

Медицинская библиотека · Journal of medicinal chemistry · 2026

Structure-Guided Design, Synthesis, and Evaluation of Novel 6-Methoxyquinoline-4-carboxamide Derivatives as First-in-Class Nano-Molar B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma.

Yin Hao, Yan Xiaowen, Fan Bo, Kong Xiangye, Gu Congying, Zhou Wang, Xu Shiping, Yin Zenglin, Zhang Min, Wang Youchen, Liu Hongyan, Feng Junli, Ge Lei, Li Jiacheng, Dong Tangtai, Yang Yong, Zhang Dayong, Dai Beiying, Zhang Menghan

СтатьяПеревод пока не подготовлен

Аннотация

Beta-1,3-glucuronosyltransferase (B3GAT3) is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis, serving as a desirable anti-HCC target. Based on our micromolar lead TMLB-C16 (IC50 = 6.22-6.53 μM, KD = 3.96 μM), 60 novel derivatives were designed via systematic structure-activity relationship optimization. The optimized candidate TMLB-G9 is the first nanomolar B3GAT3 inhibitor bearing a 6-methoxyquinoline-4-carboxamide scaffold. It exhibits stronger B3GAT3 binding affinity (KD = 0.72 μM) than both TMLB-C16 and natural substrate UDP-GlcUA (KD = 1.32 μM). TMLB-G9 exhibits potent antiproliferative activity against Huh7 and Hep3B cells (IC50 = 0.31-0.36 μM) and broad-spectrum antitumor efficacy. It suppresses HCC colony formation, migration, and invasion, while inducing G0/G1 arrest and apoptosis. With good in vivo tolerance and safety, TMLB-G9 exhibited superior anti-HCC activity to TMLB-C16 in two HCC xenograft models. In conclusion, TMLB-G9 is a promising B3GAT3 inhibitor worthy of further development for HCC therapy.

Для цитирования: Yin Hao, Yan Xiaowen, Fan Bo, Kong Xiangye, Gu Congying, Zhou Wang, Xu Shiping, Yin Zenglin, Zhang Min, Wang Youchen, Liu Hongyan, Feng Junli, Ge Lei, Li Jiacheng, Dong Tangtai, Yang Yong, Zhang Dayong, Dai Beiying, Zhang Menghan. Structure-Guided Design, Synthesis, and Evaluation of Novel 6-Methoxyquinoline-4-carboxamide Derivatives as First-in-Class Nano-Molar B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma.. Journal of medicinal chemistry. 2026. DOI: 10.1021/acs.jmedchem.6c02080.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.